JPMorgan Chase & Co. Increases Labcorp (NYSE:LH) Price Target to $330.00

Labcorp (NYSE:LH) had its price target lifted by stock analysts at JPMorgan Chase & Co. from $319.00 to $330.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 16.92% from the company’s current price.

A number of other brokerages have also issued reports on LH. Weiss Ratings upgraded shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, February 10th. UBS Group cut their target price on shares of Labcorp from $325.00 to $320.00 and set a “buy” rating on the stock in a research note on Wednesday, October 29th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Robert W. Baird upped their price objective on Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Labcorp in a research note on Tuesday. Ten equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $302.75.

Labcorp Stock Up 1.3%

Labcorp stock opened at $282.26 on Wednesday. The company has a market capitalization of $23.40 billion, a PE ratio of 26.98, a price-to-earnings-growth ratio of 1.73 and a beta of 1.03. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.35 and a current ratio of 1.42. Labcorp has a fifty-two week low of $209.38 and a fifty-two week high of $293.72. The firm has a 50 day moving average price of $265.13 and a 200 day moving average price of $269.08.

Labcorp (NYSE:LH) last released its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, topping analysts’ consensus estimates of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The company had revenue of $3.52 billion for the quarter, compared to analysts’ expectations of $3.56 billion. During the same period in the prior year, the firm earned $3.45 earnings per share. The firm’s revenue was up 5.6% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Research analysts expect that Labcorp will post 16.01 earnings per share for the current year.

Insider Transactions at Labcorp

In related news, EVP Jonathan C. Meltzer sold 87 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $290.42, for a total transaction of $25,266.54. Following the completion of the sale, the executive vice president owned 2,782 shares in the company, valued at $807,948.44. The trade was a 3.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Adam H. Schechter sold 5,273 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $284.38, for a total value of $1,499,535.74. Following the completion of the transaction, the chief executive officer directly owned 87,343 shares of the company’s stock, valued at $24,838,602.34. This trade represents a 5.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.84% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of LH. Caldwell Trust Co acquired a new stake in Labcorp during the 2nd quarter worth $25,000. Financial Gravity Companies Inc. purchased a new position in shares of Labcorp during the second quarter worth about $26,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Labcorp during the fourth quarter worth about $26,000. Hilton Head Capital Partners LLC purchased a new stake in shares of Labcorp in the 4th quarter valued at about $27,000. Finally, JPL Wealth Management LLC acquired a new stake in shares of Labcorp in the 3rd quarter valued at about $28,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp News Summary

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: JPMorgan raised its price target to $330 and kept an “overweight” rating, signaling sizable upside versus recent levels and giving the stock institutional momentum. JPMorgan raises price target
• Positive Sentiment: Robert W. Baird lifted its target to $326 and maintained an outperform view — another vote of confidence from sell‑side analysts. Baird raises target
• Positive Sentiment: Q4 results showed EPS above consensus ($4.07 vs. $3.95) and management set FY2026 EPS guidance (17.55–18.25), which supports earnings momentum and helped lift sentiment. Q4 deep dive
• Positive Sentiment: Analyst and screener writeups from Zacks highlight both momentum and value characteristics for LH, attracting style‑specific buyers. Zacks momentum
• Positive Sentiment: Brokerage consensus sits around “Moderate Buy,” reinforcing broad analyst support. Consensus Moderate Buy
• Neutral Sentiment: Labcorp’s push into an Alzheimer’s blood test and a senior neurology hire sparked a valuation debate — the move could drive long‑term growth if clinical/commercial milestones are met, but timing and commercialization risks mean near‑term impact is uncertain. Alzheimer’s test story
• Neutral Sentiment: Coverage notes and roundups (Globe & Mail, MSN) describe mixed analyst views — useful for context but not immediately market‑moving. Analysts conflicted MSN roundup
• Negative Sentiment: Revenue for the quarter came in slightly below consensus and management noted volume headwinds, which keeps some investors cautious about near‑term top‑line growth. Q4 earnings snapshot

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.